IL6 and COVID-19: Due to the postulated regulatory role of IL-6 at this stage, tocilizumab would be no longer effective in these cases; conversely, activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, which is typical of hyperferritinemic syndromes, would be crucial also in critical COVID-19 (7), and therapies targeting IL-1, such as anakinra, could still be effective (95).